encorafenib

Overview

Encorafenib is a selective BRAF V600E/K inhibitor approved in combination with binimetinib for BRAF V600-mutant melanoma and in combination with cetuximab for BRAF V600E-mutant colorectal cancer.

Evidence in the corpus

• Encorafenib (BRAF inhibitor) was among MAPK-pathway directed therapies evaluated across BRAF fusion-positive tumors (N=241, 52 histologies at MSK); combination BRAF+MEK inhibition was less durable (median 1 month) than MEK inhibitor monotherapy (median 8 months) across all treated patients PMID:38922339.

Resistance mechanisms

• Not directly characterized in the corpus.

Cancer types (linked)

• LUAD

Sources

• PMID:38922339

This page was processed by crosslinker on 2026-05-04.